Circulating microRNA alternations in primary hyperuricemia and gout.
Bohatá J, Horváthová V, Pavlíková M, Stibůrková B.
Arthritis Res Ther. 2021 Jul 10;23(1):186. doi: 10.1186/s13075-021-02569-w.
PMID:34246297
Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements.
Li Q, Li X, Wang J, Liu H, Kwong JS, Chen H, Li L, Chung SC, Shah A, Chen Y, An Z, Sun X, Hemingway H, Tian H, Li S.
BMJ Open. 2019 Aug 24;9(8):e026677. doi: 10.1136/bmjopen-2018-026677.
PMID:31446403
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.
N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373.
PMID:16339094
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
Terkeltaub R.
Drugs. 2023 Nov;83(16):1501-1521. doi: 10.1007/s40265-023-01944-y. Epub 2023 Oct 11.
PMID:37819612
How should we manage asymptomatic hyperuricemia?
Chalès G.
Joint Bone Spine. 2019 Jul;86(4):437-443. doi: 10.1016/j.jbspin.2018.10.004. Epub 2018 Oct 11.
PMID:30316974
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators.